AMEND news in Tag: Medullary Thyroid Cancer
-
Cryoablation of bone metastases in thyroid and adrenocortical cancers
This study looked at a minimally invasive treatment called cryoablation, which uses extreme cold to destroy cancer that has spread to the bones, in people with thyroid (including MTC) or adrenocortical cancer.
Click here for more information
-
Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A
This study followed people with MEN2A who had their thyroid removed to understand how often long-term blood tests for calcitonin are really needed.
Click here for more information
-
The prostate is a common site of disease in patients with MEN2B and MTC
A recent study looked at young men with MEN2B (also known as MEN3), which causes medullary thyroid cancer. Doctors found that problems in the prostate were more common than previously thought, even in teenagers.
Click here for more information
-
Rescheduled MTC Webinar Confirmed
We are pleased to confirm the new date for our rescheduled webinar on sporadic medullary thyroid cancer (spMTC). Come and join us on Wednesday 19th November, 2025, from 19:00-20:30, and hear from and quiz our esteemed expert medical speakers, Drs Kate Newbold and Daniel Morganstein from The Royal Marsden Hospital in London.
Click here for more information and to book
-
Webinar for Sporadic MTC Patients
AMEND is delighted to be hosting a free, live webinar for the sporadic medullary thyroid cancer (MTC) community on Wednesday 18th June from 19:00-20:30. Our expert speakers are Consultant Endocrinologist, Dr Daniel Morganstein, and Consultant Clinical Oncologist, Dr Kate Newbold, both from the Royal Marsden Hospital in London. We hope you can join us.
Click here to register
-
Selpercatinib – Can you Help?
AMEND is preparing a patient group submission for the Scottish Medicine's Consortium for the assessment of selpercatinib for use in metastatic MTC with the hope of getting it approved. Can you help us by sending us your input?
Click here for more information
-
NETS in RETS
November 10th each year is NET Cancer Day, initiated by the International Neuroendocrine Cancer Alliance, of which AMEND is a member representing genetic neuroendocrine tumour syndromes. To better explain the link between NETs and RETS (rare endocrine tumours and syndromes), join us for our webinar, NETs in RETS, with Professor Karim Meeran on Thursday 9th November from 18:00-19:00.
Click here for more information
-
AMEND Annual Patient Information Day Success
The sun was shining on Saturday 20th May in London for our Annual Patient Information Day, and our venue beside the Regent’s Canal was the perfect place to receive all the members of our rare endocrine diseases communities who had booked to attend.
Click here to read more
-
AMEND Invited to Host Session at ThyCa 2022 Survivor’s Conference
We are honoured to have been invited by ThyCa to participate in their 2022 virtual Thyroid Cancer Survivor's Conference, by developing a session about MTC in MEN2 and MEN3, to be held on Friday 16th September at 6pm UK-time.
Click here for more information
-
Selpercatinib Approved for Metastatic MTC
In September, selpercatinib (also known as LOXO) was approved in England (Cancer Drugs Fund) and Scotland (Interim Basis) for use in metastatic RET-mutation medullary thyroid cancer (MTC) as well as other RET-fusion positive thyroid cancers.